NCT04566393 2026-01-28
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
xCures
AVM Biotechnology Inc
TVAX Biomedical
Aveta Biomics, Inc.
Kyowa Kirin Co., Ltd.
Istari Oncology, Inc.
Genexine, Inc.
Celldex Therapeutics